Geriatric Assessment at Discharge From the Intensive Care Unit in Patients Aged 75 Years and Older: a Feasibility Study
NCT ID: NCT06513130
Last Updated: 2025-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
70 participants
INTERVENTIONAL
2024-11-01
2027-01-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The admission of these patients remains controversial, with questions about the benefit to elderly patients, both in terms of in-hospital and distant survival, as well as induced morbidity or subsequent quality of life: functional status is impaired in up to two-thirds of survivors.
The challenge of identifying the patients most able to withstand a stay is a major one. Indeed, a stay in intensive care represents a major stress for the organism, due to the acute condition associated with one or more organ failure(s). Bed rest, immobilization and the use of drugs are responsible for formidable complications in the elderly: muscle-wasting, loss of adaptation to physical effort, loss of autonomy, delirium and agitation, all of which have their own long-term impact.
While many studies have looked at the prognostic factors on admission of these patients, and the selection of the patient with the greatest probability of surviving the intensive care unit (ICU), improving the outcome of patients who survive to the ICU stay remains a little-investigated subject. However, the impact of physical and psychological disturbances induced by these patients' stay in intensive care is major, and their detection and management could be elements of interest in improving the care of this population. However, the feasibility of carrying out such an assessment immediately after an ICU stay has yet to be evaluated. The aim of this study would be to evaluate the feasibility of a geriatric assessment at the end of the ICU stay (or within 7 days of discharge) and at 6 months. This study is a prospective, randomized, single-center, open-label interventional study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of a Transitional Care Program on 30-Day Hospital Readmissions for Elderly Patients Discharged From a Short Stay Geriatric Ward
NCT02421133
Preventive Approach for the Management of the Main Geriatric Risks
NCT05128097
Evaluation of the Impact of a Paramedical Training Program for Nurses and Nursing Assistants on the Length of Stay and Prevention of Hospital Iatrogenic Complications in Elderly Patients
NCT05936515
Prevalence Study : Elderly Patients and Rehabilitation in ICU. Impact of Frailty.
NCT03326635
Early Rehospitalization of Persons Aged 75 Years or Older Admitted to a Geriatric Post-emergency Unit.
NCT06239935
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group with geriatric assessment
Patients will be assessed by a geriatric physician, in a global (clinical, physical, psyochological and social) approach at the end of the ICU stay or in the 7 days following.
In addition to the first visit in the group "without geriatric assessment", will be collected:
* Living conditions (home, proxy, home support)
* Quality of life (SF-36)
* Covi test and 4-item Geriatric Depression Scale
* Katz-ADL and IADL
* History of fall, mobility assessment
* Nutritional status (BMI, albuminemia, Mini Nutritionnal Assesment)
* Cognitive assessment (Mini-mental State Examination)
The visit at month 6 will be the same in both groups
Geriatric assessment in the 7 days following ICU discharge.
ICU survivors will be assessed by a geriatric physician, in a global (clinical, physical, psyochological and social) approach at the end of the ICU stay or in the 7 days following ICU discharge.
Group without geriatric assessment
At the end of the ICU stay or in the 7 days following, will be collect:
* Medical and surgical history, Charlson comorbidity index,
* Living place
* Regular treatment (number and class)
* ICU trajectory: ICU length of stay, reason for ICU admission, severity scores (SOFA and SAPS 2 score), organ supports requirement and duration
* Limitation of life-sustaining therapy decision
At 6 month after ICU discharge, patients will be evaluated during a post-ICU consultation, where will be recorded:
* Living conditions (home, proxy, home support)
* Quality of life (SF-36)
* Covi test and 4-item Geriatric Depression Scale
* Katz-ADL and IADL
* History of fall, mobility assessment
* Nutritional status (BMI, albuminemia, Mini Nutritionnal Assesment)
* Cognitive assessment (Mini-mental State Examination)
* Regular treatment (number and class)
* Hospitalizations between ICU discharge and M6
* Additional comorbidity
* Family burden assessment (mini-Zarit)
No geriatric assessment in the 7 days following ICU discharge.
No geriatric assessment in the 7 days following ICU discharge.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Geriatric assessment in the 7 days following ICU discharge.
ICU survivors will be assessed by a geriatric physician, in a global (clinical, physical, psyochological and social) approach at the end of the ICU stay or in the 7 days following ICU discharge.
No geriatric assessment in the 7 days following ICU discharge.
No geriatric assessment in the 7 days following ICU discharge.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted to the intensive care unit, for whatever reason, and having survived their stay, considered as leaving the intensive care unit.
* Subjects affiliated to a health insurance scheme
* Able to understand the aims and risks of the research and to give dated, signed informed consent,
* In the event of confusion on leaving the intensive care unit, a close relative available to give dated, signed informed consent, with the patient's consent collected as soon as his or her condition permits.
Exclusion Criteria
* Subject moribund, or whose life expectancy as estimated by the clinician in charge is less than 1 month
* Patient not living in Bas-Rhin (visit to M6)
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julien DEMISELLE
Role: PRINCIPAL_INVESTIGATOR
Hôpitaux Universitaires de Strasbourg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Médecine Intensive - Réanimation / CHU Strasbourg - France
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9107
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.